دوره 4، شماره 3 - ( 6-1401 )                   جلد 4 شماره 3 صفحات 10-1 | برگشت به فهرست نسخه ها

‎ 10.47176/sjmshm.4.3.1

XML English Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Determining the Predicting Value of the Shock Index in Early Prediction of Mortality in Patients with Acute Myocardial Infarction under Primary PCI. sjmshm 2022; 4 (3) :1-10
URL: http://sjmshm.srpub.org/article-3-185-fa.html
تعیین ارزش پیش بینی کننده شاخص شوک در پیش بینی اولیه مرگ و میر در بیماران مبتلا به انفارکتوس حاد میوکارد تحت PCI اولیه. نشریه علوم پزشکی و مدیریت سلامت. 1401; 4 (3) :1-10

URL: http://sjmshm.srpub.org/article-3-185-fa.html

تعیین ارزش پیش بینی کننده شاخص شوک در پیش بینی اولیه مرگ و میر در بیماران مبتلا به انفارکتوس حاد میوکارد تحت PCI اولیه
چکیده:   (296 مشاهده)
مقدمه: شاخص شوک (ضربان قلب (HR) تقسیم بر فشار خون سیستولیک (SBP) ممکن است نقش مهمی در ارزیابی و پیش‌بینی حوادث قلبی عروقی، به ویژه در بیماران مبتلا به بیماری ایسکمیک قلبی تحت عمل‌های قلبی داشته باشد. مطالعه حاظر ارزش اخباری شاخص شوک در پیش‌بینی زودهنگام مرگ و میر بیماران مبتلا به انفارکتوس حاد میوکارد تحت PCI اولیه را بررسی میکند. روش: 200 بیمار مبتلا به انفارکتوس حاد میوکارد که کاندید PCI اولیه بودند در بیمارستان سیدالشهدا ارومیه در مطالعه شرکت کردند. در زمان بستری، شاخص های ضربان قلب و فشار خون تعیین و شاخص شوک (ضربان قلب (HR) تقسیم بر فشار خون سیستولیک (SBP)) محاسبه شد و از این رو بیماران به دو گروه تقسیم شدند: یک گروه با شاخص کمتر یا مساوی 0.7 و گروه دیگر با شاخص بیش از 0.7 . برای تجزیه و تحلیل مطالعه فوق از نرم افزار SPSS 21 استفاده شد.نتایج: در این مطالعه فراوانی مرگ و میر بیمارستانی در گروه با شاخص شوک کمتر نسبت به گروهی که شاخص شوک بالاتری داشتند کمتر بود (0.001 = p-value). با توجه به ارزیابی سطح زیر منحنی ROC، شاخص شوک از قابلیت بالایی برای پیش‌بینی مرگ و میر بیمارستانی برخوردار بود (منطقه زیر منحنی ROC = 0.895؛ p-value<0.001). در نقطه جیاتی 0.7، شاخص شوک با حساسیت 70 درصد و ویژگی 88.4 درصد پیش بینی کننده مرگ و میر بیمارستانی بود. به طور مشابه، با توجه به ارزیابی سطح زیر منحنی ROC، شاخص شوک از قابلیت بالایی برای پیش‌بینی مرگ و میر میان مدت پس از ترخیص از بیمارستان برخوردار بود (منطقه زیر منحنی ROC = 0.888؛ p-value<0.001). در نقطه حیاتی 0.7، شاخص شوک با حساسیت 100 درصد و ویژگی 86.9 درصد پیش بینی کننده مرگ و میر میان مدت بود. نتیجه گیری: شاخص شوک در پیش بینی مرگ و میر بیمارستانی و مرگ و میر میان مدت در بیماران مبتلا به انفارکتوس حاد میوکارد تحت PCI اولیه از ارزش بالایی برخوردار بود.
واژه‌های کلیدی: PCI اولیه، انفارکتوس حاد میوکارد، شاخص شوک، مرگ و میر
متن کامل [PDF 421 kb]   (167 دریافت)    
نوع مطالعه: پژوهشي | موضوع مقاله: قلب و عروق و پزشکی قلب و عروق
دریافت: 1401/2/24 | ویرایش نهایی: 1401/4/20 | پذیرش: 1401/4/30 | انتشار: 1401/6/3
فهرست منابع
1. American Heart Association. Cardiovascular disease statistics. 2006; http://www. americanheart.org
2. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: The National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000; 36: 2056-2063. [DOI:10.1016/S0735-1097(00)00996-7] [PMID]
3. Furman MI, Dauerman HL, Goldberg RJ, Yarzebski J, Lessard D, Gore JM. Twenty two year (1975 to 1997) trends in the incidence, in-hospital and long-term case fatality rates from initial Q-wave and non-Q-wave myocardial infarction: a multi-hospital, community-wide perspective. J Am Coll Cardiol. 2001; 37: 1571-1580. [DOI:10.1016/S0735-1097(01)01203-7] [PMID]
4. Khademvatani K, Basiri M, Alinejad V, Seyed Mohammad Zad MH. Prevalence and correlates of aortic root dilatation in patients with essential hypertension admitted to Seyedoshohada Hospital, Urmia 2012-2013. J Glob Pharm Tech. 2016; 02(8): 01-06.
5. Seyed Mohammad Zad MH, Khalili N, Alinejad V, Khadem Vatani K. Is there a correlation between coronary artery ectasia and neutrophil-lymphocyte ratio?. J Glob Pharm Tech. 2016; 02(8): 01-06.
6. Khademvatan K, Alinejad V, Eghtedar S, Rahbar N, Agakhani N. Survey of the relationship between metabolic syndrome and myocardial infarction in hospitals of Urmia University of medical sciences. Glob J Health Sci. 2014 Sep 18; 6(7 Spec No): 58-65. doi: 10.5539/gjhs.v6n7p58 [DOI:10.5539/gjhs.v6n7p58] [PMID] []
7. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circ. 2001; 104: 2158-2163. [DOI:10.1161/hc4301.098254] [PMID]
8. Haghjoo M, Hajahmadi M, Fazelifar AF, Sadr-Amel MA. Efficacy and safety of different antitachycardia pacing sites in the termination of ventricular tachycardia in patients with biventricular implantable cardioverter-defibrillator. Europace, 2011; 13(4): 509-513 [DOI:10.1093/europace/euq513] [PMID]
9. Heris SO, Rahimi B, Faridaalaee G, Hajahmadi M, Sayyadi H, Naghipour B. QT dispersion after thrombolytic therapy. Int Cardiovasc Res J. 2014; 8(4): 161-165
10. Rahimi Darabad B, Vatandust J, Pourmousavi Khoshknab MM, Hajahmadi Poorrafsanjani M. Survey of the effect of opioid abuse on the extent of coronary artery diseases. Glob J Health Sci. 2014; 6(7): 83-91. [DOI:10.5539/gjhs.v6n7p83] [PMID] []
11. Hajahmadi Poorrafsanjani M, Rahimi Darabad B. Evaluate the sensitivity and specificity echocardiography in trans-Doppler and tissue Doppler method in the estimation of left ventricular end-diastolic pressure. Glob J Health Sci. 2014; 6(7): 92-97. [DOI:10.5539/gjhs.v6n7p92] []
12. Gibson CM. NRMI and current treatment patterns for ST-elevation myocardial infarction. Am Heart J. 2004; 148:Suppl: S29-S33. [DOI:10.1016/j.ahj.2004.09.012] [PMID]
13. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circ. 2001; 104: 365-372. [DOI:10.1161/01.CIR.104.3.365] [PMID]
14. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circ. 2005; 111: 3481-3488. [DOI:10.1161/CIRCULATIONAHA.105.537878] [PMID]
15. Freedman JE. Molecular regulation of platelet-dependent thrombosis. Circ. 2005; 112: 2725-2734. [DOI:10.1161/CIRCULATIONAHA.104.494468] [PMID]
16. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circ. 1977; 56: 786-794. [DOI:10.1161/01.CIR.56.5.786] [PMID]
17. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol. 2006; 97:Suppl 10A: 13F-25F. [DOI:10.1016/j.amjcard.2006.03.005] [PMID]
18. Grines CL, Cox DA, Stone GW, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999; 341: 1949-1956. [DOI:10.1056/NEJM199912233412601] [PMID]
19. Stone GW, Brodie BR, Griffin JJ, et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. J Am Coll Cardiol. 1998; 31: 23-30. [DOI:10.1016/S0735-1097(97)00439-7] [PMID]
20. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 1994; 343: 311-322. [Erratum, Lancet, 1994; 343: 742]. [DOI:10.1016/S0140-6736(94)91161-4]
21. Juliard J-M, Himbert D, Golmard J-L, et al. Can we provide reperfusion therapy to all unselected patients admitted with acute myocardial infarction? J Am Coll Cardiol. 1997; 30: 157-164. [DOI:10.1016/S0735-1097(97)00119-8] [PMID]
22. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary- artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993; 329: 1615-1622. [Erratum, N Engl J Med. 1994; 330: 516]. [DOI:10.1056/NEJM199311253292204] [PMID]
23. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circ. 1993; 87: 1829-1839. [DOI:10.1161/01.CIR.87.6.1829] [PMID]
24. Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003; 42: 7-16. [DOI:10.1016/S0735-1097(03)00506-0] [PMID]
25. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 2003; 361: 13-20. https://doi.org/10.1016/S0140-6736(03)13013-9 https://doi.org/10.1016/S0140-6736(03)12113-7 [DOI:10.1016/S0140-6736(03)12750-X] [PMID]
26. Nallamothu BK, Wang Y, Magid DJ, et al. Relation between hospital specialization with primary percutaneous coronary intervention and clinical outcomes in ST-segment elevation myocardial infarction: National Registry of Myocardial Infarction 4 analysis. Circ. 2006; 113: 222-229. [DOI:10.1161/CIRCULATIONAHA.105.578195] [PMID]
27. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction - executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circ. 2004; 110: 588-636. [Erratum, Circ. 2005; 111: 2013]. [DOI:10.1161/01.CIR.0000134791.68010.FA] [PMID]
28. Ahmed S, Antman EM, Murphy SA, et al. Poor outcomes after fibrinolytic therapy for ST-segment elevation myocardial infarction: impact of age (a meta-analysis of a decade of trials). J Thromb Thrombolysis. 2006; 21: 119-129. [DOI:10.1007/s11239-006-5485-9] [PMID]
29. Thune JJ, Hoefsten DE, Lindholm MG, et al. Simple risk stratification at admission to identify patients with reduced mortality from primary angioplasty. Circ. 2005; 112: 2017-2021. [DOI:10.1161/CIRCULATIONAHA.105.558676] [PMID]
30. Taher T, Fu Y, Wagner GS, et al. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol. 2004; 44: 38-43. [DOI:10.1016/j.jacc.2004.03.041] [PMID]
31. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346: 957-966. [DOI:10.1056/NEJMoa013404] [PMID]
32. Valgimigli M, Percoco G, Malagutti P, et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA. 2005; 293: 2109-2117. [DOI:10.1001/jama.293.17.2109] [PMID]
33. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006; 355: 1093-1104. [DOI:10.1056/NEJMoa062006] [PMID]
34. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med. 2006; 355: 1105-1113. [DOI:10.1056/NEJMoa062598] [PMID]
35. Piper WD, Malenka DJ, Ryan TJ Jr, et al. Predicting vascular complications in percutaneous coronary interventions. Am Heart J. 2003; 145: 1022-1029. [DOI:10.1016/S0002-8703(03)00079-6] [PMID]
36. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1993; 328: 673-679. [DOI:10.1056/NEJM199303113281001] [PMID]
37. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002; 287: 1943-1951. [Erratum, JAMA. 2002; 287: 3212.] [DOI:10.1001/jama.287.15.1943] [PMID]
38. Bartholomew BA, Harjai KJ, Dukkipati S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol. 2004; 93: 1515-1519. [DOI:10.1016/j.amjcard.2004.03.008] [PMID]
39. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circ. 2003; 108: 2769-2775. [DOI:10.1161/01.CIR.0000103623.63687.21] [PMID]
40. DeGeare VS, Stone GW, Grines L, et al. Angiographic and clinical characteristics associated with increased in-hospital mortality in elderly patients with acute myocardial infarction undergoing percutaneous intervention (a pooled analysis of the primary angioplasty in myocardial infarction trials). Am J Cardiol. 2000; 86: 30-34. [DOI:10.1016/S0002-9149(00)00824-9] [PMID]
41. Goss JE, Chambers CE, Heupler FA Jr. Systemic anaphylactoid reactions to iodinated contrast media during cardiac catheterization procedures: guidelines for prevention, diagnosis, and treatment. Cathet Cardiovasc Diagn. 1995; 34: 99-104. [DOI:10.1002/ccd.1810340403] [PMID]
42. Mehta RH, Harjai KJ, Grines L, et al. Sustained ventricular tachycardia or fibrillation in the cardiac catheterization laboratory among patients receiving primary percutaneous coronary intervention: incidence, predictors, and outcomes. J Am Coll Cardiol. 2004; 43: 1765-1772. [DOI:10.1016/j.jacc.2003.09.072] [PMID]
43. Yang EH, Gumina RJ, Lennon RJ, Holmes DR Jr, Rihal CS, Singh M. Emergency coronary artery bypass surgery for percutaneous coronary interventions: changes in the incidence, clinical characteristics, and indications from 1979 to 2003. J Am Coll Cardiol. 2005; 46: 2004-2009. [DOI:10.1016/j.jacc.2005.06.083] [PMID]
44. Wharton TP Jr, Grines LL, Turco MA, et al. Primary angioplasty in acute myocardial infarction at hospitals with no surgery on-site (the PAMI-No SOS study) versus transfer to surgical centers for primary angioplasty. J Am Coll Cardiol. 2004; 43: 1943-1950. [DOI:10.1016/j.jacc.2004.03.013] [PMID]
45. Wharton TP Jr. Should patients with acute myocardial infarction be transferred to a tertiary center for primary angioplasty or receive it at qualified hospitals in community? The case for community hospital angioplasty. Circ. 2005; 112: 3509-3520.
46. Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL. What is the risk of stent thrombosis associated with the use of paclitaxeleluting stents for percutaneous coronary intervention? A meta-analysis. J Am Coll Cardiol. 2005; 45: 941-946. [DOI:10.1016/j.jacc.2004.11.064] [PMID]
47. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol. 2005; 45: 954-959. [DOI:10.1016/j.jacc.2004.11.065] [PMID]
48. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005; 293: 2126-2130. [DOI:10.1001/jama.293.17.2126] [PMID]
49. Keeley EC, Grines CL. Should patients with acute myocardial infarction be transferred to a tertiary center for primary angioplasty or receive it at qualified hospitals in the community? The case for emergency transfer for primary percutaneous coronary intervention. Circ. 2005; 112: 3520-3532.
50. Abe N, Miura T, Miyashita Y, Hashizume N, Ebisawa S, Motoki H, Tsujimura T, Ishihara T, Uematsu M, Katagiri T, Ishihara R, Tosaka A, Ikeda U. Long-term prognostic implications of the admission shock index in patients with acute myocardial infarction who received percutaneous coronary intervention. Angiol. 2016 Jun 14; pii: 0003319716653885. [DOI:10.1177/0003319716653885] [PMID]
51. Spyridopoulos I, Noman A, Ahmed JM, Das R, Edwards R, Purcell I, Bagnall A, Zaman A, Egred M. Shock-index as a novel predictor of long-term outcome following primary percutaneous coronary intervention. Eur Heart J Acute Cardiovasc Care. 2015 Jun; 4(3): 270-7. doi: 10.1177/2048872614561480 [DOI:10.1177/2048872614561480] [PMID]
52. Bilkova D, Motovska Z, Widimsky P, Dvorak J, Lisa L, Budesinsky T. Shock index: a simple clinical parameter for quick mortality risk assessment in acute myocardial infarction. Can J Cardiol. 2011 Nov-Dec; 27(6): 739-742. doi: 10.1016/j.cjca.2011.07.008 [DOI:10.1016/j.cjca.2011.07.008] [PMID]
53. Wilson WM, Andrianopoulos N, Clark D, Duffy SJ, Brennan A, Harries I. Long-term predictors of mortality after percutaneous coronary intervention in the era of drug-eluting stents. Am J Cardiol. 2011 Oct 1; 108(7): 936-42. doi: 10.1016/j.amjcard.2011.05.024 [DOI:10.1016/j.amjcard.2011.05.024] [PMID]
54. Shangguan Q, Xu JS, Su H, Li JX, Wang WY, Hong K, et al. Modified shock index is a predictor for 7-day outcomes in patients with STEMI. Am J Emerg Med. 2015 Aug; 33(8): 1072-1075. doi: 10.1016/j.ajem.2015.04.066 [DOI:10.1016/j.ajem.2015.04.066] [PMID]
55. Spyridopoulos I, Noman A, Ahmed JM, Das R, Edwards R, Purcell I, et al. Shock-index as a novel predictor of long-term outcome following primary percutaneous coronary intervention. Eur Heart J Acute Cardiovasc Care. 2015 Jun; 4(3): 270-277. doi: 10.1177/2048872614561480 [DOI:10.1177/2048872614561480] [PMID]
56. Huang B, Yang Y, Zhu J, Liang Y, Tan H, Yu L, et al. Usefulness of the admission shock index for predicting short-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2014 Nov 1; 114(9): 1315-1321. doi: 10.1016/j.amjcard.2014.07.062 [DOI:10.1016/j.amjcard.2014.07.062] [PMID]
ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
CAPTCHA
بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.